New Small-Scale Expression Packages: RushMab- Ready in just 8 days! LEARN MORE

Biointron Insights: Antibody Industry Report (Q2 2024 Insights, Trends & Analysis) LEARN MORE

Biointron - Antibody Discovery, Antibody Production, Stable cell line, Protein Expression, CRO

Antibody Antibody Antibody

Services & Products

About Us

  • 0 +
    Years of Experience
  • 0 +
    Employees
  • 0 +
    Companies Served Globally
  • 0 +
    Delivered Annually

Why you should choose us

  • Pioneering Antibody Solutions

    We specialize in antibody expression, discovery, and optimization with internationally recognized automated production standards - offering superior services at market- competitive rates with efficient turnaround times.

  • Unique Cell Line Commercialization

    We possess exclusive re-licensing rights for the commercialization of the CHO-K1BN cell line licensed from ECACC.

  • Global Collaborative Excellence

    Our partnerships with over 1,500 global biotech and pharmaceutical entities, coupled with our collaborative advancements in international clinical stages, solidify our esteemed position in the industry.

  • Trust and Exclusive ownership

    We commit to complete confidentiality - preserving the exclusive ownership rights of the antibodies we produce for our clients.

Antibody

Engage with Biointron, your dependable partner for efficient, affordable, and top-tier custom antibody solutions.

About Biointron

Founded in 2012, and certified to ISO 9001:2015, Biointron is a CRO (Contract research organization) specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.


Biointron is a leading high-throughput recombinant antibody/protein expression and discovery service provider. From gene sequence to purified antibodies, it just takes 2 weeks. Biointron has delivered tens of thousands of recombinant antibodies for more than 1,500 biotech and pharma companies all over the world.

Read More Read More

Client Voices: Biointron Success Stories

Learn from our partners and clients about the transformative impact of Biointron's expertise.

"We evaluated the 6 proteins you produced for us and we were quite pleased by the results. our internal assessments of the molecules are very encouraging so we would like to potentially expand this further."

— AstraZeneca

"We have tested both batches of the antibodies you sent us. They're active and give comparable results with little batch to batch variation."

— AbbVie

"Excellent.The protein quality and activity was high and up to our standards, we appreciate the help and the work.The short timeline for the production is the main factor Biointron differs from other CROs."

— Moderna

"Great working with you, I've been highly impressed and recommending you to many in my network."

— Sanofi

"I just wanted to give you a quick heads-up regarding the expression we conducted at Biointron. Essentially, everything went well and was super fast, so we are all very much satisfied."

— Merck KGaA

"BioIntron was the best from the three: it was the only company that was able to express all the sequences and the yield for those proteins that the other two companies also could express was, generally, higher."

— ImmuVia, LLC

Our Latest News and Stories

This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year

Antibodies are versatile molecules that perform a range of effector functions, many of which engage different arms of the immune system. Their modes of action extend beyond simple antigen binding, enabling the activation of various immune mechanisms that lead to pathogen neutralization and clearance. These functions include blocking molecular interactions, activating the complement system, and linking the humoral immune response to cellular immune responses via Fc receptor engagement.

Sep 06, 2024
Blog

In today’s competitive biotech landscape, intellectual property (IP) protection has become an essential pillar in fostering innovation and collaboration across drug discovery and development. By offering clear IP terms and no royalty fees,pharmaceutical companies and research institutes

Sep 06, 2024
Blog

In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#

Mar 23, 2024
Company News

Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.

Mar 15, 2024
Company News

Celebrate International Women's Day with Biointron's female workforce!

Mar 15, 2024
Company News

Time: September 3 - 5, 2024
Location: Boston, MA
Booth: #4

Time: September 30 - October 3, 2024
Location: Boston, MA
Booth: #510

Time: October 3 - 4, 2024
Location: San Diego, CA
Booth: #4

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.